Delivery Order SPE2DB20D2001-SPE2DB25FPNRN
- Not listed
- The Defense Logistics Agency awarded a $26,582.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation medication used to treat chronic obstructive pulmonary disease. The contract was competitively awarded with no set-aside designation and is set for completion by August 4, 2025. This delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $13,832.28 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 (60 count), a combination inhaler medication used for chronic obstructive pulmonary disease treatment. This competitively awarded, firm fixed-price delivery order was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a $16,409.89 firm fixed price delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation medication used to treat chronic obstructive pulmonary disease. The award, issued on July 22, 2025, is a non-set-aside competitive procurement with an ultimate completion date of July 23, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation medication used to treat chronic obstructive pulmonary disease. The contract, valued at $10,848.83, was competitively awarded with no set-aside designation and carries a firm fixed price structure. Performance is scheduled to be completed by August 4, 2025, with the work to be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $13,817.08 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This competitively awarded, firm fixed price contract was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a $3,024.00 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award was made through open competition with no...
- The Defense Logistics Agency awarded a delivery order valued at $1,351.10 to AmerisourceBergen Drug Corp on August 18, 2025, for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation medication used to treat chronic obstructive pulmonary disease. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance completed by August 19, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,534.20 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This firm fixed price contract, awarded on August 15, 2025, represents a competitive award with no set-aside designation and will be completed by August 18, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,350.27 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by August 26, 2025. The award was processed on August 25, 2025, with performance taking place at AmerisourceBergen's corporate...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNRNDelivery Order
The Defense Logistics Agency (DLA) awarded a $22,946.07 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhaler medication used to treat chronic obstructive pulmonary disease. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal procurement portfolio demonstrates significant capability in delivering both brand-name and generic medications across multiple therapeutic domains through competitive, firm fixed price arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.9k | 9/8/25 |